CN1106392A - 环丙烷衍生物及含这些衍生物的抗病毒剂 - Google Patents

环丙烷衍生物及含这些衍生物的抗病毒剂 Download PDF

Info

Publication number
CN1106392A
CN1106392A CN94117485A CN94117485A CN1106392A CN 1106392 A CN1106392 A CN 1106392A CN 94117485 A CN94117485 A CN 94117485A CN 94117485 A CN94117485 A CN 94117485A CN 1106392 A CN1106392 A CN 1106392A
Authority
CN
China
Prior art keywords
methyl
pyrimidine dione
encircles
beta
methylol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN94117485A
Other languages
English (en)
Chinese (zh)
Inventor
大西智之
辻尚志
岩山聪
奥西昌彦
向井千贺
关山隆顕
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ajinomoto Co Inc
Original Assignee
Ajinomoto Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co Inc filed Critical Ajinomoto Co Inc
Publication of CN1106392A publication Critical patent/CN1106392A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CN94117485A 1993-10-21 1994-10-21 环丙烷衍生物及含这些衍生物的抗病毒剂 Pending CN1106392A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP26349093 1993-10-21
JP263490/93 1993-10-21

Publications (1)

Publication Number Publication Date
CN1106392A true CN1106392A (zh) 1995-08-09

Family

ID=17390246

Family Applications (1)

Application Number Title Priority Date Filing Date
CN94117485A Pending CN1106392A (zh) 1993-10-21 1994-10-21 环丙烷衍生物及含这些衍生物的抗病毒剂

Country Status (7)

Country Link
US (1) US5496824A (2)
EP (1) EP0649840B1 (2)
KR (1) KR950011530A (2)
CN (1) CN1106392A (2)
CA (1) CA2134050A1 (2)
DE (1) DE69429569T2 (2)
TW (1) TW271438B (2)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69628750T2 (de) * 1996-02-22 2004-04-29 Samjin Pharm, Co., Ltd. Neue antivirale, homocarbozklische nukleosidderivate von substituierten pyrimidindionen, verfahren zu ihrer herstellung und zusammensetzungen, die diese als aktiven bestandteil enthalten
NZ622795A (en) 2011-11-10 2015-12-24 Aratana Therapeutics Nv Method for preparing cyclopropane derivatives
CA2863500A1 (en) 2012-01-20 2013-07-25 Aratana Therapeutics Nv Eye drop composition

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4863927A (en) * 1987-05-11 1989-09-05 Merck & Co., Inc. 1-(2-hydroxymethyl)cycloalkylmethyl)-5-substituted uracils
CA2042931A1 (en) * 1990-05-24 1991-11-25 Robert Zahler Fluorinated bis (hydroxymethyl) cyclobutyl purines and pyrimidines
USH1142H (en) * 1990-11-05 1993-02-02 Optically active cyclobutyl pyrimidine
EP0502690B1 (en) * 1991-03-05 1999-12-01 Ajinomoto Co., Inc. Cyclopropane derivative

Also Published As

Publication number Publication date
CA2134050A1 (en) 1995-04-22
KR950011530A (ko) 1995-05-15
EP0649840A1 (en) 1995-04-26
US5496824A (en) 1996-03-05
DE69429569T2 (de) 2002-09-19
DE69429569D1 (de) 2002-02-07
EP0649840B1 (en) 2002-01-02
TW271438B (2) 1996-03-01

Similar Documents

Publication Publication Date Title
CN1050603C (zh) 非对映选择性合成核苷的方法中所使用的中间产物的制备方法
CN1030916C (zh) 制备羟甲基(亚甲基环戊基)嘌呤和嘧啶的方法
CN1054603C (zh) 三取代的苯基衍生物及含有该衍生物的药物组合物
CN1036575A (zh) 制备双(羟甲基)环丁基嘌呤和嘧啶的方法
CN1094038A (zh) 氨基取代的吡唑
CN1088581A (zh) 内皮素受体拮抗剂
CN1055182A (zh) N-(吡咯并《2，3-d》嘧啶-3-基酰基)-谷氨酸衍生物
CN1030075A (zh) 取代的吡咯类
CN1413205A (zh) 具有抗肿瘤活性的2－(1h－吲哚－3－基)－2－氧代－乙酰胺
CN1051730A (zh) 3r，4r-乙基-[(1-甲基-1h-咪唑-5-基)甲基]-2-吡咯烷酮的n-取代的衍生物
CN1108657A (zh) 雪花胺衍生物、其制备方法及其作为药物的用途
CN1732173A (zh) 高纯酞衍生物及其制备方法
CN1195759C (zh) 制备苯并噁嗪衍生物及其中间体的方法
CN1098102A (zh) 7-氧杂二环庚烷羧酸前列腺素同系物中间体及其制法
CN86102077A (zh) 碳化青霉烯中间体的制备方法
CN1050022A (zh) 去氢环黄皮酰胺衍生物的制备方法
CN1098415A (zh) 亚水杨基氨基过渡金属配合物及其制法
CN88101674A (zh) 色酮衍生物
CN1106392A (zh) 环丙烷衍生物及含这些衍生物的抗病毒剂
CN1228082A (zh) 双吲哚基马来酰亚胺的合成
CN1020598C (zh) 将拟除虫菊酯异构体转化成活力较高的种类的方法
CN1026785C (zh) 黄皮酰胺，新黄皮酰胺及其衍生物的制备方法
CN1048041A (zh) 二苯并[1，5]二氧杂环辛烷-5-酮衍生物及其制备方法和药物用途
CN1052114A (zh) 新的非离子射线照相造影剂
CN1028993C (zh) 生产新的核酸衍生物的方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C01 Deemed withdrawal of patent application (patent law 1993)
WD01 Invention patent application deemed withdrawn after publication